Ultragenyx Sold Priority Review Voucher for $210 Million
The company monetized a regulatory asset gained after the FDA approved its gene therapy for glycogen storage disease type Ia.
Updated on Oct. 13, 2026 in Biotech
Live Poll
Do government priority review voucher programs effectively encourage the development of rare disease therapies?
Ultragenyx has sold a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million. The voucher was awarded following the FDA approval of GENGLYCOS, a gene therapy treatment for glycogen storage disease type Ia.
Why it matters
The PRV program is designed to incentivize the development of therapies for rare pediatric conditions by allowing companies to sell these regulatory assets to fund future research. Monetizing these vouchers provides critical capital for continued drug development in niche clinical areas.
Ultragenyx secured the $210 million transaction through the sale of a voucher awarded by the FDA after the agency approved GENGLYCOS for glycogen storage disease type Ia.
The players
Ultragenyx
A biotechnology company focused on developing gene therapies and other novel medicines for rare and ultra-rare genetic diseases.
FDA
The United States federal agency responsible for regulating pharmaceuticals, which oversees the approval of new treatments and the issuance of priority review vouchers.
The details
The FDA awards these vouchers to developers of successful treatments for rare pediatric diseases to encourage innovation in underserved therapeutic areas. Once awarded, a voucher can be redeemed to shorten the FDA review timeline for a future drug application or sold to another firm. In this case, the transaction remains subject to the expiration of the federal Hart-Scott-Rodino waiting period, which governs antitrust review of corporate mergers and acquisitions.
Timeline
October 13, 2026: The sale of the voucher was announced.
The Tech Race
This transaction underscores the ongoing reliance on the FDA's Rare Pediatric Disease Priority Review Voucher program as a vital financial bridge for biotech firms. It follows a consistent trend of companies leveraging these regulatory assets to sustain investment in high-cost gene therapy research.
The capital injection from this sale allows Ultragenyx to continue funding its pipeline of treatments for rare genetic conditions. While this specific sale does not alter the availability of existing drugs, it ensures the financial viability of future clinical trials for patients awaiting new therapies.
The takeaway
Monetizing regulatory vouchers serves as a key financial mechanism for biotech companies to pivot from product approval to sustained R&D. Investors and observers should monitor the expiration of the Hart-Scott-Rodino waiting period to confirm the transaction's completion.
Further reading
Learn more about the latest innovations and regulatory shifts in the Biotech sector.
Source note: This article includes information reported by BioXconomy.
Live Poll
Do government priority review voucher programs effectively encourage the development of rare disease therapies?
